International Journal of Academic Health and Medical Research (IJAHMR)
ISSN: 2643-9824
Vol. 9 Issue 7 July - 2025, Pages: 52-58

Exploring Effective Treatments for Vitiligo: A Comprehensive Review

Shaymaa Hasan Abbas [1*], Deleen Abd Al Wahab Hasoon[2]

[1*] Lecturer, department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
[2] Lecturer Dr, department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
[*] E-mail: shaymaamustafa8@ uomustansiriyah.edu.iq

Abstract: *Vitiligo is a chronic autoimmune skin disorder that results in the progressive and selective loss of melanocytes, leading to well-defined depigmented macules on the skin. Although it does not affect physical health directly, its psychological and emotional consequences are profound, especially when affecting visible body areas. The disease is believed to result from multiple interrelated mechanisms including autoimmune processes, genetic predisposition, oxidative stress, and neurochemical involvement. Several therapeutic strategies have been explored to manage vitiligo. Topical therapies such as corticosteroids and calcineurin inhibitors have shown efficacy, particularly in early and localized cases. Phototherapy using narrowband ultraviolet B (NB-UVB) or psoralen plus ultraviolet A (PUVA) remains a mainstay for generalized vitiligo. In addition, surgical methods including grafting techniques and melanocyte transplantation are recommended for patients with stable disease who fail to respond to medical therapy. Herbal medicine, especially from Indian and Chinese traditions, also presents promising outcomes in stimulating melanogenesis. Recently, novel therapies such as Janus kinase (JAK) inhibitors and miRNA-based approaches have emerged as potential game changers in vitiligo treatment. Recent progress in vitiligo therapy has facilitated the emergence of novel treatment strategies designed to decelerate disease progression. Tackling inequalities in healthcare access and enhancing awareness of the psychological burden of vitiligo are essential steps toward improving patient outcomes on a global scale.*

Keywords: Vitiligo, Calcineurin Inhibitors, Phototherapy, Herbal Therapy

Introduction

Vitiligo is a common acquired depigmentation disorder resulting from the destruction of melanocytes, the pigment-producing cells in the epidermis. It affects approximately 0.5–2% of the world's population, regardless of race or gender [1]. Clinically, it manifests as white patches on the skin and mucous membranes, with symmetrical distribution being most common [2]. Although the exact cause is unknown, the autoimmune hypothesis is the most widely accepted, supported by evidence of circulating antibodies against melanocytes and the frequent co-occurrence of other autoimmune disorders such as thyroiditis and type 1 diabetes [3,4]. In addition to autoimmunity, oxidative stress, genetic susceptibility, and neurochemical factors have been implicated in vitiligo pathogenesis. Recent research highlights the role of resident memory T cells (TRM), which may persist in the skin and cause recurrence even after treatment-induced repigmentation [5]. Given its visible nature, vitiligo significantly affects patients' self-esteem, social interactions, and overall quality of life [3,4]. Management is therefore not limited to medical treatment alone but must include psychological support and patient education. A comprehensive therapeutic plan—combining topical agents, phototherapy, surgical methods, and novel targeted therapies—should be tailored based on individual patient profiles.

Review Protocol

Research Questions

This review addresses four key research questions to explore the scope of available therapies for vitiligo:

RQ1: What are the most commonly used medical treatments for vitiligo?

RQ2: What surgical interventions are available for vitiligo, and in which cases are they indicated?

RQ3: What herbal or traditional therapies are used in vitiligo treatment?

RQ4: What constitutes a comprehensive approach to vitiligo management?

Search Strategy

A structured literature review was conducted using a combination of backward and forward reference search techniques through Google Scholar. Foundational review articles were identified using key terms such as vitiligo treatment, NB-UVB, topical corticosteroids, phototherapy, grafting in vitiligo, herbal therapies, and JAK inhibitors. Backward referencing helped locate relevant older studies, while forward referencing identified newer research citing those studies. The selected literature was screened based on scientific credibility, date of publication, relevance to clinical practice, and therapeutic outcomes.

Results of RQ1: Medical Therapies for Vitiligo

Vitiligo treatment often begins with medical therapy aimed at stopping melanocyte destruction and promoting repigmentation. These include topical corticosteroids, calcineurin inhibitors, vitamin D analogues, phototherapy, laser treatments, and new molecular-targeted drugs.

Topical Corticosteroids

are anti-inflammatory agents widely used in localized vitiligo. They suppress the immune response and slow disease progression. Effectiveness: Most useful in early or active localized lesions, particularly on the trunk and face. Limitations: Long-term use may cause skin atrophy, telangiectasia, or striae. Recommended use is limited to 2–3 months in strong formulations [6].

Calcineurin Inhibitors

Tacrolimus and pimecrolimus are topical immunomodulators that inhibit T-cell activation without the side effects associated with corticosteroids. Use: Particularly effective on the face, neck, and intertriginous areas. Safety: Suitable for long-term application, even in children. Efficacy: Similar to mild corticosteroids in effect but safer on sensitive skin [6].

Vitamin D Analogues

These include calcipotriol and tacalcitol. They support melanocyte proliferation and modulate the local immune response. Effectiveness: Limited when used alone; more beneficial in combination with NB-UVB or topical steroids. Application: Often used as adjuncts in combination regimens for enhanced effect [6].

Phototherapy

Phototherapy remains a cornerstone in vitiligo management. It involves controlled exposure to ultraviolet light to stimulate melanocyte activity and immune modulation.

Narrowband Ultraviolet B (NB-UVB)

Mechanism: Stimulates remaining melanocytes and suppresses local autoimmune response. Protocol: Administered 2–3 times per week for 3–6 months or longer. Effectiveness: Considered the gold standard for generalized vitiligo; safe for use in both adults and children. Advantages: Minimal side effects, no systemic toxicity [7].

Psoralen + UVA (PUVA)

Mechanism: Involves oral or topical psoralen, a photosensitizer, followed by UVA exposure. Limitations: Higher risk of side effects like nausea, phototoxicity, and long-term risk of skin cancer. Use: Less preferred today due to the safety and effectiveness of NB-UVB[7].

Laser Therapy

Laser treatments provide localized stimulation of melanocytes with minimal exposure to surrounding healthy skin [8].

Excimer Laser (308 nm)

Use: Targets specific patches with high-intensity UVB light. Effectiveness: Particularly beneficial for focal or segmental vitiligo. Advantages: Faster response in small areas; often combined with topical agents [9].

CO_2 Fractional Laser

Mechanism: Creates micro-injuries that promote melanocyte migration and enhance repigmentation. Use: Usually as an adjunct to topical. Notes: May improve penetration of other topical agents and stimulate skin remodeling (24).

Results of RQ2: Surgical Interventions in Vitiligo

Surgical treatment is considered for patients with stable vitiligo, defined by the absence of new or expanding lesions for at least 6–12 months [10]. It is typically employed when medical treatments fail to yield sufficient repigmentation, especially in localized or segmental types [11,12].

Tissue Grafting Techniques

*Punch Grafting

Involves transplanting small circular skin grafts (1–2 mm) from a pigmented donor area to the depigmented site. Advantages: Simple, inexpensive, and does not require advanced equipment. Disadvantages: May result in cobblestone appearance and donor site scarring (39).

*Suction Blister Epidermal Grafting

Uses the epidermal layer from suction-induced blisters on the donor site. Advantages: Better cosmetic outcomes and less invasive. Limitations: Time-consuming and requires technical expertise [13].

*Split-Thickness Skin Grafting

Involves removing a thin layer of skin containing epidermis and part of the dermis for transplantation. Use: Applied in larger or resistant vitiliginous patches. Considerations: Higher risk of donor site complications and pigment mismatch [13].

Hair Follicle Transplantation

Hair follicles, rich in melanocyte stem cells, are transplanted into depigmented skin. Use: Especially useful in hairy regions like the scalp, beard, or eyebrows. Mechanism: Stimulates gradual repigmentation around the follicle [13].

*Cellular Grafting Techniques

Cultured Melanocyte Transplantation (CMT)

Melanocytes are harvested and cultured in vitro to increase cell number before being transplanted to depigmented skin. Advantages: Suitable for large areas; excellent cosmetic results. Limitations: Requires laboratory setup and higher costs. High repigmentation success, especially when followed by NB-UVB [14,15]

Non-Cultured Epidermal Cell Suspension (NCES)

Involves immediate preparation and transplantation of melanocytes and keratinocytes from a small donor sample. Advantages: Faster and less expensive than cultured techniques[15,16]

Results of RQ3: Herbal Therapies in Vitiligo

Herbal medicine is widely practiced in traditional systems such as Ayurveda, Traditional Chinese Medicine (TCM), and Indian medicine.

Table (1): Examples of herbal agents used for vitiligo treatment [17].

Herbal Agent	Origin	Main Effects
Psoralea corylifolia	India/China	Phototoxic, stimulates melanogenesis
Curcuma longa (Turmeric)	India	Anti-inflammatory, antioxidant
Cassia occidentalis	India	Enhances pigment production
Eclipta prostrata	Asia	Promotes melanocyte growth, antioxidant effect
Sophora flavescens	China	Immunomodulatory
Atractylodes japonica	China/Japan	Supports skin regeneration

Herbal remedies are believed to work through several mechanisms [17], including:

- Phototoxicity: several components of plant increase skin sensitivity to UV, stimulating pigmentation.

- Anti-inflammatory Effects: some herbs reduce inflammation and oxidative stress that damages melanocytes.
- Immunomodulation: Some herbs suppress autoimmune processes targeting pigment cells.
- Stimulation of Melanocytes: Certain extracts directly promote melanocyte activity and migration.

While these remedies are widely used, most lack large-scale, standardized clinical trials, and may carry risks of allergic reactions or irritation.

Results of RQ4: Comprehensive Management of Vitiligo

Vitiligo is more than a skin disorder—it affects patients psychologically, emotionally, and socially. Effective treatment requires a holistic approach that addresses not just pigmentation, but the overall quality of life.

Key Components of Comprehensive Vitiligo Management

1. Mental Health Counseling and Psychosocial Assistance

- Emotional and Social Impact: The visible nature of vitiligo can profoundly affect a person's self-image, self-confidence, and overall quality of life, often leading to anxiety, depression, and social withdrawal[18,19-21].
- Psychological Interventions: Psychological counseling, cognitive behavioral therapy (CBT), relaxation methods, and stress management techniques have proven effective in helping individuals cope with these emotional challenges and improve psychological well-being. [19, 22]
- Multidisciplinary Approach: Integrating mental health support within a multidisciplinary care model—featuring dermatologists, psychologists, and other healthcare providers—can significantly improve patient resilience and quality of life. [19, 23].

2. Strategies for Coping and Community Inclusion [19, 22],

- Enhancing Treatment Adherence: In pediatric cases, therapeutic play and robust family involvement can reduce fear of medical procedures and improve treatment compliance, which is essential for managing vitiligo effectively[19].
- Fostering a Positive Social Environment:Promoting social inclusion through supportive and accepting environments can greatly benefit individuals with vitiligo. This may include conflict resolution strategies and techniques to strengthen relationships with family and the broader community [22].

3. Patient Education and Awareness Programs

- Improving Patient Understanding: Providing patients with in-depth, accurate information about vitiligo—including its causes, treatment modalities, and potential complications—empowers them to make informed decisions and engage actively in their treatment journey[24].

4. Management of Treatment-Associated Issues

- Managing Expectations: It is essential to set realistic expectations, as vitiligo treatment often requires long-term commitment and may not always result in full repigmentation [25].

Utilizing Combination Therapies:

Combining different treatment methods—such as topical agents, phototherapy, and surgical options—can sometimes yield better results. Studies have shown that integrated treatment strategies may enhance clinical outcomes in specific cases [26].

Table (2): Comparative treatments of vitiligo

Treatments	Mechanisms	Efficacy of treatment	Major Findings
Corticosteroids	Suppress autoimmune activity and reduce localized inflammation.	Highly effective for localized vitiligo (OR: 14.32, 95% CI: 2.45–83.72).	Skin atrophy is a common side effect [27].
Calcium Modulators	Enhance the effectiveness of NB-UVB when used in combination.	More effective than NB-UVB alone (RR: 1.67, 95% CI: 1.21–2.31).	Tacalcitol demonstrated better outcomes than Calcipotriol [28].

Calcineurin Inhibitors	Block T-cell activation to reduce inflammatory responses (e.g., tacrolimus, pimecrolimus).	Moderate repigmentation (≥50%) observed in 38.5% of patients.	Combining with phototherapy yields enhanced results [29].
Laser Therapy	Excimer light (MEL) stimulates melanocyte function and melanin synthesis.	≥50% repigmentation achieved in 62.1% of patients within 3 months using NB-UVB.	Phototherapy combination further improves success [30].
CO2 Fractional Laser	Induces micro-injury to promote collagen formation and pigmentation restoration.	≥75% repigmentation when combined with other treatments (RR: 2.80, 95% CI: 1.29–6.07).	Effective as an adjunctive therapy [31].
Methotrexate	Used as an immunosuppressant in conjunction with NB-UVB therapy.	Reduces disease progression effectively when combined with phototherapy.	Better efficacy than standalone treatments; side effects are generally mild [32]
JAK Inhibitors	Target JAK signaling to block autoimmune activity (e.g., Tofacitinib).	Up to 92% repigmentation with combined NB-UVB therapy.	Effective, but associated with systemic adverse effects [33].
5-Fluorouracil (5FU)	Stimulates pigmentation when paired with microneedling techniques.	>75% repigmentation observed (OR: 4.47, 95% CI: 2.39–8.35, P < 0.00001).	Liposomal formulations enhance therapeutic efficacy [34].

Emerging Therapies and Future Clinical Directions in Vitiligo

Recent advancements in vitiligo therapy have introduced novel strategies aimed at halting disease progression. One promising target is the IFN-γ–CXCL9/10–CXCR3 axis, which has gained attention due to the development of OPZELURA, a topical agent for treating non-segmental vitiligo. Parallel investigations are focusing on miRNA-based therapies, although issues related to off-target effects highlight the need for rigorous preclinical assessments. These approaches also demand reliable delivery systems and assurance of both chemical and biological stability [19].

For stable vitiligo, current management includes topical corticosteroids, calcineurin inhibitors, phototherapy, and in some cases, surgical interventions such as melanocyte transplantation. However, a deeper understanding of vitiligo's underlying mechanisms has led to the emergence of targeted molecular therapies. Among these, Janus kinase (JAK) inhibitors have demonstrated both clinical efficacy and acceptable tolerability. Nevertheless, there remain concerns about potential systemic adverse effects and risks of reactivating latent infections.

Ongoing research is actively mapping the cytokine profile involved in vitiligo pathogenesis, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF. Preliminary efforts to inhibit these molecules have shown promise in both animal models and limited human studies. Furthermore, while microRNA-based therapeutics and adoptive regulatory T cell (Treg) therapy are still in experimental stages, continued investigation is essential to evaluate their long-term safety and clinical effectiveness [35].

Conclusion

Vitiligo is a multifactorial autoimmune condition with profound psychosocial implications. Though not physically harmful, it significantly affects patients' emotional well-being and quality of life. Current therapeutic modalities for vitiligo, such as calcineurin inhibitors, corticosteroids, surgical techniques, and phototherapy, demonstrate variable efficacy in controlling disease progression and facilitating repigmentation. Nonetheless, a significant obstacle lies in maintaining sustained long-term responses and preventing relapse, issues that affect many patients. Emerging approaches in regenerative medicine, particularly Janus kinase (JAK) inhibitors, show considerable promise in improving treatment efficacy. Moreover, advancements in biologic and targeted therapies, grounded

in a deeper molecular understanding of vitiligo, are leading toward more personalized treatment strategies. Equally important is the need to address inequities in healthcare access and to raise awareness about the psychological burden associated with vitiligo, both of which are essential to achieving improved patient outcomes on a global scale.

1- Abduljabbar R. Vitiligo Causes and Treatment: A Review. Haya The Saudi Journal of Life Sciences. 2024
2- Nudel R, Allesøe R, Werge T, Thompson W, Rasmussen S, Benros M. An immunogenetic investigation of 30 autoimmune and autoinflammatory diseases and their links to psychiatric disorders in a nationwide sample. Immunology. 2022;168:622–639.
3- Girish M. 543 - Early repigmentation of stable vitiligo through point-of-care melanocyte transfer using non-cultured autologous skin cell suspension. British Journal of Dermatology. 2024
4- Madhusudhan M. Early Repigmentation of Stable Vitiligo through Point-of Care Melanocyte Transfer Using Non-Cultured Autologous Skin Cell Suspension. SKIN The Journal of Cutaneous Medicine. 2024
5- Boniface K, Seneschal J. Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. Experimental Dermatology. 2019;28:656–661.
6- Garg, B.J., Saraswat, A., Bhatia, A., & Katare, O.P. (2010). Topical treatment in vitiligo and the potential uses of new drug delivery systems. Indian Journal of Dermatology, Venereology, and Leprology, 76, 231.
7- Gaikwad, Aparna Vijay; Bharatia, Pravin R.. Study of efficacy of phototherapy (psoralen with ultraviolet A and narrow-band ultraviolet B) in vitiligo. Pigment International 3(1):p 11-16, Jan–Jun 2016.
8- Dillon AB, Sideris A, Hadi A, Elbuluk N. Advances in Vitiligo: An Update on Medical and Surgical Treatments. ˜The œJournal of clinical and aesthetic dermatology. 2017;10 1:15–28.
9- Anbar, T.S., El-Sawy, A.E., Attia, S.K., Barakat, M.T., Moftah, N.H., El Ammawy, T.S., Abdel-Rahman, A.T., & El-Tonsy, M.H. (2012). Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: Histopathological, immuno-histochemical and ultrastructural study. Photodermatology, Photoimmunology & Photomedicine, 28, 17-25.
10- Bae, J. M., & Ju, H. J. (2020). Surgical interventions for vitiligo. Journal of the Korean Medical Association, 63(12), 748–755.
11- Lan, C.-C. E. (2012). comment:A comparative study on 100% tca versus 88% phenol for the treatment of vitiligo. Our Dermatology Online, 3(3), 187.[35]
12- Gamal, A., Moftah, N., & El-Barbary, R. (2020). Updates in Surgical Treatment of Vitiligo. Journal of Recent Advances in Medicine.
13- Bae JM, Lee JH, Kwon HS, Kim J, Kim DS. Motorized 0.8 mm micro-punch grafting for refractory vitiligo: A retrospective study of 230 cases. J Am Acad Dermatol. 2018; 79(4): 720-27
14- Jin R, Hong W. Autologous cultured melanocyte transplantation for the treatment of genital vitiligo. Chinese Journal of Dermatology. 2019 Jun 15;52(6):429–30.
15- Pandya, V., Shah, B., Bilimoria, F., & Parmar, K. (2005). A study of autologous melanocyte transfer in treatment of stable vitiligo. Indian Journal of Dermatology, Venereology and Leprology, 71(6), 393.
16- Yao, L., Li, S., Song, Y., Zhong, S., & Liu, Y. (2017). Successful Treatment of Stable Vitiligo by Low-Density Cultured Autologous Melanocyte Transplantation Combined With Narrowband Ultraviolet B Therapy. Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], 43(10), 1281–1287
17- Lakhani, D.M., & Deshpande, A.S. (2014b). Various Treatments for Vitiligo: Problems Associated and Solutions. Journal of Applied Pharmaceutical Science, 4, 101-105.
18- Kruger C, Panske A, Schallreuter K. Disease-related behavioral patterns and experiences affect quality of life in children and adolescents with vitiligo. International Journal of Dermatology. 2014;53.
19- Shen, J., Xu, A., Wei, F., & Wang, C. (2024). Psychological intervention in vitiligo: Current status and future directions. Frontiers in Psychology, 15, 1166939.
20- Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003; 1(1): 58
21- Mattoo, S. K., Handa, S., Kaur, I., Gupta, N., & Malhotra, R. (2002). Psychiatric morbidity in vitiligo: prevalence and correlates in India. Journal of the European Academy of Dermatology and Venereology, 16(6), 573-578
22- Ajuwon OA, Animashaun ES, Chiekezie NR. Crisis intervention, mediation, counseling, and mentoring in schools: Building resilient educational communities. International journal of applied research in social sciences. 2024
23- M M, Sheelam DrPK. Unveiling Psychological Perspectives on Aging Minds and Cancer: A Review. International Journal of Current Science Research and Review. 2023
24- Van Geel, N., Speeckaert, M., Brochez, L., Lambert, J., & Speeckaert, R. (2014). Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. Journal of the European Academy of Dermatology and Venereology, 28(6), 741-746.
25- Taieb A, Alomar A, Böhm M, Dell'anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: The European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5-

26- Mansouri P, Rahbar M, Nilforoushzadeh M, Shati M, Amirkhani M. Fractional CO2 Laser Versus Microneedling Combined with Narrowband Ultraviolet and Topical Steroid for Treating Non-Segmental Vitiligo in Treatment-Resistant Localizations: A Comparative Randomized Clinical Trial Study. Journal of lasers in medical sciences. 2024;15:e38.
27- Njoo, M. D., Spuls, P. I., Bos, J. D., et al. (2002). Randomized controlled trials on corticosteroids for vitiligo. JAMA Dermatology.
28- Liu, X., Yao, Z., Wang, Y., et al. (2022). Calcium modulators in vitiligo treatment: A meta-analysis. International Immunopharmacology, 109.
29- Lee, J. H., Kwon, H. S., Jung, H. M., et al. (2018). Efficacy of calcineurin inhibitors in vitiligo. British Journal of Dermatology, 178(1).
30- Bae, J. M., Lee, S. C., Hong, B. Y., et al. (2016). Narrowband UVB phototherapy: Efficacy for vitiligo. Photodermatology, Photoimmunology & Photomedicine, 32(2).
31- Abdelghani, Rania. (2017). Fractional carbon dioxide laser for hypopigmented lesions. 10.13140/RG.2.2.20947.07205.
32- Singh, H., Kumaran, M. S., Bains, A., et al. (2015). Oral methotrexate for vitiligo treatment. Dermatology, 231(3).
33- Song, H., Hu, Z., Zhang, S., et al. (2022). Effectiveness of JAK inhibitors in vitiligo. Dermatologic Therapy, 35(11).
34- Kohaf, N. A., Sarsik, S. M., Salman, S., et al. (2020). Microneedling and 5FU in vitiligo. Systematic Review.
35- Feng, Y. and Lu, Y., 2022. Advances in vitiligo: Update on therapeutic targets. Frontiers in immunology, 13, p.986918.